A study that used data from the ENGAGE AF-TIMI 48 which was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2, evaluated NT-proBNP as a predictor of stroke recurrence in anticoagulated patients [27]. This evidence concerns the gene NPPB and stroke disorder.